|
Epilepsy is a debilitating disorder that affects millions of individuals in the US and throughout the world. We are developing novel treatments for epilepsy that are currently undergoing preclinical and clinical investigation.
Learn More >
|
|
|
Asthma is a lung disease characterized by airway obstruction, airway inflammation, and increased airway responsiveness to a variety of stimuli. Typical symptoms include shortness of breath, cough and wheezing in response to particular stimuli. The disease varies in severity from a mild intermittent form to a severe persistent form. While asthma cannot be cured, most people with asthma are able to be treated so that they are able to live active lives.
Learn More >
|
|
|
|
Pain affects more individuals in the US than diabetes, heart disease and cancer combined. Icagen is pursuing next-generation ion channel modulators to manage various pain states more effectively and with fewer side effects compared to available therapies. We are currently collaborating with Pfizer on compounds targeting three different sodium channel subtypes.
Learn More >
|
|
|
|
We have broad based research efforts spanning across a number of therapeutic areas.
Learn More >
|
|
|
We have established an integrated set of core technologies for the discovery of drugs that act upon ion channel targets.
Learn More >
|
|
